Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has shared an update.
Hansoh Pharmaceutical Group has transferred its exclusive Greater China licence for KiOmed Pharma’s osteoarthritis treatment KiOmedine vs One to Jiangsu Hengrui Pharmaceuticals, following a strategic review of its portfolio and resource allocation priorities. The medical chitosan knee injection, approved by China’s NMPA as a medical device in August 2025 but not yet commercialised, will now be developed and marketed by Hengrui, which has a stronger presence in orthopedics.
Under a novation and transfer structure, Hansoh’s three original licensee subsidiaries will exit the licence agreement and assign all related rights and obligations to Hengrui for RMB131 million, allowing Hansoh to recover its development costs on a cost basis. The board said the deal, classified as revenue in the ordinary course of business and not a notifiable or connected transaction under Hong Kong listing rules, aligns with Hansoh’s long-term strategic focus while positioning the product with a partner better equipped for its commercial rollout.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$47.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a China-based pharmaceutical company engaged in the research, development, manufacture and sale of medicines across multiple therapeutic areas. Through its subsidiaries, the group has historically pursued partnerships and licensing deals to expand its portfolio in key markets including Mainland China, Hong Kong, Macau and Taiwan.
Average Trading Volume: 9,595,210
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$234.1B
Learn more about 3692 stock on TipRanks’ Stock Analysis page.